Statement from the Global HIV Vaccine Enterprise Board of Directors:
William Snow Stepping Down as Director of the Global HIV Vaccine Enterprise
November 8, 2016 - The Board of Directors of the Global HIV Vaccine Enterprise, an alliance of independent organizations committed to accelerating the development of HIV vaccines, today announced that William Snow will step down after nearly five years as the director of the Enterprise Secretariat. Mr. Snow will remain a senior advisor to the secretariat and the Enterprise Board. Enterprise Board Vice President Gerald Voss will serve as interim director.
Bill Snow joined the Enterprise Secretariat as its director in April 2012. Among his many accomplishments in this role, Bill has led Enterprise activities such as the Timely Topics in HIV Vaccines series, which has expanded the Enterprise's strategic convening functions and made them more rapidly responsive to emerging issues and challenges in the field; expanded the Enterprise's focus on the needs of funders, scientists and industry partners; supported collaborations of pan-African scientists involved in HIV vaccine research; and worked to promote the exchange of manufacturing and regulatory intelligence that can advance the search for an HIV vaccine. Another recent Enterprise initiative, the Product Development Boot Camp, works to familiarize vaccine research stakeholders with concepts and tools used by industry to drive product development of HIV vaccine candidates.
During Snow's tenure, the Enterprise also became the host secretariat for the global HIV Research for Prevention (HIVR4P) conference, the first and only scientific meeting dedicated exclusively to biomedical HIV prevention research. The premier HIVR4P conference was held in 2014, and the equally successful second HIVR4P meeting recently concluded in Chicago. At this year's conference, Ambassador Deborah Birx, US Global AIDS Coordinator and herself a long-standing HIV vaccine researcher and advocate, announced that the Enterprise is establishing a fellowship program in honor of Snow's contribution to and interest in the interface between science and advocacy in the development of HIV vaccines.
“This is an exciting and promising time in HIV vaccine research, one that the Global HIV Vaccine Enterprise has contributed to bringing about, and one that I believe the Enterprise will continue to help lead in the future,” said Bill Snow. “Directing the Enterprise Secretariat has been one of the greatest and most rewarding challenges of my life. I am humbled by the commitment of our partners, stakeholders and staff to promoting the exchange of information and creating the scientific, policy and funding environment that can lead to an effective and practical vaccine for HIV.”
Prior to assuming the directorship of the Enterprise Secretariat, Bill Snow had a long and distinguished history in the HIV vaccine field. He was a member of the original Coordinating Committee and Board of the Enterprise and was its treasurer when the Enterprise received its initial funding in 2005. He is also co-founder and a long-time board member of the HIV prevention research advocacy organization AVAC. Bill was instrumental in establishing national, local and global community advisory boards at the NIH clinical trial networks AVEG, HIVNET and HVTN. He has served on the NIAID AIDS Vaccine Research Subcommittee, the NIH Vaccine Research Center Scientific Advisory Working Group and, over the past 20 years, on advisory committees and boards for almost every HIV vaccine group.
“The Global HIV Vaccine Enterprise Board of Directors extends its deepest gratitude to Bill Snow for his years of service to the search for an HIV vaccine, and in particular for his extraordinary service to the Enterprise, which he helped to create,” said Enterprise Board President and Chair Mitchell Warren, who is also AVAC's Executive Director. “I look forward to working with Gerald Voss, the Enterprise Board, and, most importantly, the larger community of stakeholders as we work to determine future directions for the Enterprise and to build on Bill's legacy of leadership.”
“Bill Snow has been and continues to be a tireless champion for HIV vaccine research and development,” said Enterprise Board Vice President and interim director Gerald Voss. “I look forward to working with the Board to build upon Bill's exceptional leadership in the search for an HIV vaccine and the further evolution of the Enterprise.”
More information about the Global HIV Vaccine Enterprise and efforts to develop a safe and effective vaccine against HIV is available at vaccineenterprise.org.
About the Global HIV Vaccine Enterprise :
The Global HIV Vaccine Enterprise is an alliance of independent organizations committed to accelerating the development of HIV vaccines. The Enterprise accomplishes this through coordination, collaboration, knowledge sharing and efforts to attract interest, resources and funders to the field. The Enterprise also oversees the highly successful biennial HIV Research for Prevention conference, the world's first and only scientific meeting dedicated exclusively to all biomedical HIV prevention research. For further information and examples of Enterprise projects and activities, visit vaccineenterprise.org/.
"Reproduced with permission - Global HIV Vaccine Enterprise"
Global HIV Vaccine Enterprise
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
